Tagged with EG

Pharma Legal Handbook Patents and trademarks in Turkey – an overview. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. What are the basic requirements to obtain patent and trademark protection? Both…

Pharma Legal Handbook An insight about product liability in Turkish Pharma. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. What types of liability are recognized in your jurisdiction? Medicinal product liability arises…

Pharma Legal Handbook The lowdown on the situation regarding traditional medicines and OTC products in Turkey. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. What are the regulatory requirements for traditional, herbal,…

Pharma Legal Handbook Hot-button legal issues around marketing, manufacturing, packaging & labelling and advertising in Turkish pharma. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. What is the authorization process for the marketing…

Pharma Legal Handbook Preclinical and clinical trial requirements in Turkey – a legal guide. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. Are clinical trials required to be conducted locally as a condition…

Pharma Legal Handbook An intro to the legal situation for regulatory, pricing and reimbursement in Turkey. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. What are the regulatory authorities with jurisdiction over…

France Maurice-Pierre Planel, president of the CEPS (Comité économique des produits de santé), details how the French government is unique in the way that they engage in drug pricing and comments on how the transformation of the French healthcare system will impact the CEPS’s role in price negotiation.   You are…

Spain One of the unique aspects of the system is the fragmentation linked to the country’s 17 autonomous regions The Spanish healthcare system performance is ranked as 7th in the world by the World Health Organization (WHO), beating countries such as Japan, the Netherlands, United Kingdom, and the United States. Additionally,…

France As the UK prepares to leave the European Union in March 2019, stakeholders across the European life sciences industry are busy preparing for Brexit’s potential impact on their operations. In France, the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) – the country’s drug regulator –…

Mexico Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here he discusses the new Alma-Ata Declaration that focuses on primary care and work at…

Cyprus In an exclusive interview, President Nicos Anastasiades outlines his public health priorities, the continuing importance of the pharmaceutical industry to Cyprus’s economy, and the nation’s attractiveness as an international investment destination. Ensuring our citizens’ good health is not negotiable. What are your main priorities and policies for public health for…

Regulation Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the United States, discusses the contradictory nature of Trump’s efforts to lower drug prices.    The President has forcefully pledged to provide relief to these patients and their families, but his own trade policy threatens…